text:
Dual reverb / effects processor.

£149.17 Price excludes VAT

Product lists can be submitted to HHB for a packaged quotation

Add to Product List
Add to Product List

Designed with both live sound reinforcement and home recording in mind, the MX200 has 16 reverbs, 6 delays, compressor, de-esser, chorus, flanger, phaser, tremolo / pan, rotary, vibrato, pitch shift and detune. For studio use, it has a USB interface with intuitive cross-platform VST and Audio Unit plug-in windows, allowing the MX200 to function as a “hardware plug-in” – recognized and functioning within VST and Audio Units-compatible DAWs as a plug-in effect, but still operating as a dedicated hardware unit. This USB plug-in feature allows DAW users to easily control the MX200 via the graphical interface that appears in the recording application like a plug-in, with full automation and recall features.
• Balanced or unbalanced 1/4″ jack analogue I/O
• SPDIF digital I/O
• 24-bit/48kHz A-D converters
• WinXP/Mac OSX VST GUI interface
• 4 routing configurations: dual mono, cascade, dual stereo (parallel) and mono split


Content-Type: application/http; msgtype=response

WARC-Identified-Payload-Type: text/html

WARC-Type: response

text:
Canada Soccer mourns passing of Gary Miller

Halton Hawks FC, is deeply saddened to learn of the passing of Gary Miller, who was the Director of Soccer Operations of Ontario Soccer,. Gary passed way Wednesday May 13 at the age of 63.

"Gary leaves behind a tremendous legacy on the sport of soccer in Canada, holding multiple tenures at Ontario Soccer, Canada Soccer and a number of other influential organizations over his illustrious career," Ontario Soccer said in a statement.

"I met Gary 20 years ago when he interviewed me for a coaching position at North Mississauga" said Vasco Nunes, HHFC's Coaching Director , "over the years, we became soccer competitors, but most importantly, we became friends".

"I am extremely sad to hear about Gary's passing, he was always friendly, cordial and professional, we will miss him" added Toni Marin, HHFC's Director.

We would like to offer our sincere condolences to Cindy, Gary's wife, his daughters Stephanie, Briana and son Ryan.

warcinfo:
isPartOf: CC-MAIN-2021-49
publisher: Common Crawl
description: Wide crawl of the web for November/December 2021
operator: Common Crawl Admin (info@commoncrawl.org)
hostname: ip-10-67-67-99
software: Apache Nutch 1.18 (modified, https://github.com/commoncrawl/nutch/)
robots: checked via crawler-commons 1.3-SNAPSHOT (https://github.com/crawler-commons/crawler-commons)
format: WARC File Format 1.1
conformsTo: https://iipc.github.io/warc-specifications/specifications/warc-format/warc-1.1/


text:
New 'Ghostbusters: Afterlife' Trailer Drops

October 18, 2021 5:00 PM ‐ MoviesParanormal

With a month to go until the new 'Ghostbusters' movie opens in cinemas, the latest trailer has dropped giving fans an idea of what to expect from 'Afterlife'.

'Ghostbusters: Afterlife' Trailer
The new trailer, clocking in at just over two minutes long, teases more about the upcoming 'Ghostbusters: Afterlife' movie than any of the previous teasers, in fact, perhaps a little too much.

The official international trailer, which was shared by Sony Pictures today, opens with Mckenna Grace's character, Phoebe, asking her mother - played by Carrie Coon - "what kind of scientist was grandpa?"

In the movie, Phoebe and her brother, Trevor played by 'Stranger Things' star Finn Wolfhard, go on a journey to uncover the lost legacy of their grandfather, original Ghostbuster Egon Spengler. As they attempt to "uncover the past" in order to "save the future."

The movie, which also stars Paul Rudd in the role of a local school teacher, is set in the rural town of Summerville. Where the new generation of Ghostbusters battle a series of paranormal events that seem to be emanating from an old mine in the small town.

Although the movie revolves around Phoebe, Trevor and their classmate known as 'Podcast', expect some blasts from the past, Bill Murray, Ernie Hudson, Sigourney Weaver and Annie Potts will cameo as their original characters in the 2021 movie.

In the latest trailer we see a little more of the mine, which was worked by the Shandor Mining Company, a reference to Ivo Shandor, the leader of the Cult of Gozer which was the focus of the original 1984 movie.

There's plenty of shots of ghost traps, proton packs, ECTO-1, and a ton of supernatural action, which is likely to really get fans of the original movie's ectoplasm pumping.

We also see the new incarnation of the terror dog, which originally hunted down Louis Tully and captured Dana Barrett in their apartment building on Central Park West. This time round the iconic 'Ghostbusters' demon has been recreated using a mix of puppetry and CGI, rather than claymation.

What We Know About The Movie

More From 'Ghostbusters' View All

Daily Horoscopes

You are dragging the office into your home, and family issues back to work. It seems when you are in one place, you want to be at the other and vice versa. The solution is to focus your energies on... Read More


text:
Stem Cells International

Stem Cells International / 2016 / Article

Review Article | Open Access

Volume 2016 |Article ID 7954580 |

Antonia Reale, Assunta Melaccio, Aurelia Lamanuzzi, Ilaria Saltarella, Franco Dammacco, Angelo Vacca, Roberto Ria, "Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies", Stem Cells International, vol. 2016, Article ID 7954580, 11 pages, 2016.

Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies

Academic Editor: Pavla Jendelova
Received15 Mar 2015
Revised19 Jun 2015
Accepted10 Aug 2015
Published14 Dec 2015

It was believed that vasculogenesis occurred only during embryo life and that postnatal formation of vessels arose from angiogenesis. Recent findings demonstrate the existence of Endothelial Precursor Cells (EPCs), which take partin postnatal vasculogenesis. EPCs are recruited from the bone marrow under the stimulation of growth factors and cytokines and reach the sites of neovascularization in both physiological and pathological conditions such as malignancies where they contribute to the “angiogenic switch” and tumor progression. An implementation of circulating EPCs in the bloodstream of patients with haematological malignancies has been demonstrated. This increase is strictly related to the bone marrow microvessel density and correlated with a poor prognosis. The EPCs characterization is a very complex process and still under investigation. This literature review aims to provide an overview of the functional and biological role of EPCs in haematological malignancies and to investigate their potential as a new cancer therapeutic target.

1. Introduction

Blood vessels arise through two different mechanisms: vasculogenesis and angiogenesis. Vasculogenesis is the process of the de novo formation of blood vessels, which usually occurs during embryonic life but it can also happen in postnatal life in particular conditions; angiogenesis instead is the process of vessels formation from preexisting ones [1].

The most important cells which take part in prenatal vasculogenesis are haemangioblasts, which derive from mesenchymal stem cells, and represent the precursors of endothelial and haematopoietic cells.

During embryogenesis, between days 21 and 32, when the yolk sac develops, haemangioblasts form aggregates, also known as bloods islands. In this early process, haemangioblasts form tight junction through each other, creating a primary tube formation with a lumen; then perivascular cells resembling pericytes pass into the early lumen, and finally in the late stage of vasculogenesis the development of a basal lamina induces the separation of the vessel lumen delimited by endothelial cells from perivascular cells [2].

Before the first identification of EPCs by Asahara et al. [3] in 1997, it was believed that vasculogenesis occurred only during embryo life. Since the identification of circulating EPCs, the idea of postnatal vasculogenesis was enhanced and increasing evidence suggests the contribution of EPCs in several diseases such as myocardial ischemia, stroke, retinopathy, and peripheral vascular disease and in tumor growth and progression. Considering the importance of EPCs and their involvement in postnatal vasculogenesis in both physiological and pathological conditions, many authors have investigated the role and the characterization of EPCs in order to better understand their specific markers and the mechanisms regulating their function and differentiation [4].

During postnatal vasculogenesis, EPCs are recruited from the BM, into the blood circulation to the site of damage under the stimulation of hypoxia, growth factors (GFs), and cytokines and here they differentiate into mature endothelial cells (ECs). Evidences show, that after myocardial infarction or ischemia, neovascularization occurs and promotes regeneration of cardiac and vasculature structures; thus clinical studies have been conducted in order to infuse autologous EPCs with the aim to augment the number of EPCs, favoring the remodeling process which physiologically occurs after a cardiac damage. Many studies have demonstrated the ability of EPCs to transdifferentiate into cardiomyocytes, contributing actively to the regeneration of the tissue [5].

The involvement of EPCs in wound healing is well known. Neovascularization is essential for the survival and remodeling of injured tissue. After wound healing, the secretion of both inflammatory cytokines and growth factors recruits immune cells and also EPCs, which proliferate and induce the formation of the new blood vessel and tissue regeneration which finally is remodeled [6].

Many studies also show the importance of EPCs in bone formation and osteogenesis: deficient vasculogenesis seems to be responsible for the fail of bone restoration. As well as in postmyocardial infarction, EPCs CD34+ cells are also able to transdifferentiate in osteoblasts taking part in osteogenesis themselves [7].

Finally vasculogenesis takes part also in pathological conditions such as tumor growth and is involved in tumor progression. A typical phase of both solid and haematological malignances is the so-called “angiogenic switch” which is the transition from the avascular phase to the vascular and more aggressive phase of tumor growth [8]. Vasculogenesis and angiogenesis represent two critical mechanisms which ensure tumor progression providing nutrients, growth factors, and oxygen to tumor site, favoring also metastatic processes [9]. Thus high microvessel density (MVD) correlates with poor prognosis and a reduced survival expectation [10].

2. EPCs Characterization and Biology

EPCs were first identified and isolated by Asahara et al. [3] in 1997. They isolated CD34 and vascular growth factor receptor 2 (VEGFR2) positive haematopoietic progenitor cells from adults that could differentiate into cells with an endothelial phenotype and take part in neovascularization.

Moreover EPCs have been identified as bone marrow- (BM-) derived EPCs [11] and they take part in neovascularization in different tissue injuries and remodeling.

The characterization, the identification, and the origin of EPCs are now more defined.

EPCs are part of a big heterogeneous group of cells that share the same precursor within BM and are able to induce endothelial differentiation in peripheral blood. Thus the word “EPCs” can be used to recognize cells belonging to several steps ranging from primitive haemangioblasts to completely differentiated ECs. During the past two decades, several research groups have tried to elucidate a concise characterization of EPCs without good successes. The main reason resides in the surface markers used to phenotype EPCs which are common between haematopoietic stem cells and differentiated ECs.

In a first instance, scientists believed that EPCs arose from haemangioblasts like other haematopoietic cells [12] and this idea was supported by several in vitro and in vivo assays. Indeed embryonic stem cell- (ESC-) derived blast colony forming cells (BF-CSCs), considered an in vitro haemangioblast, were able, after VEGF-A or bone morphogenic protein-4 (BMP-4) stimulation, to differentiate into endothelial or haematopoietic cells, respectively [13]. Later other in vivo experiments in mice and zebrafish embryos [14, 15] sustained the role of haemangioblasts in EPCs development. On the contrary, few studies affirmed that endothelial and haematopoietic cells did not share a common precursor cell [16]. So the presence of haemangioblast is still unclear; moreover more studies support the idea of a common cell that could differentiate into endothelial or haematopoietic cells under appropriated stimuli. Progenitor cells are different from stem cells because they lack their self-renewal capability, but EPCs maintain many stem cells abilities, including self-renewal, clonogenicity, and differentiation. Furthermore EPCs express some undifferentiated and differentiated stem cells lineage markers such as CD133, fibroblast growth factor receptor (FGFR), CD146, CXCR4, ckit, vascular endothelial cadherin (VEcadherin), platelet endothelial cell adhesion molecule 1 (CD31), von Willebrand factor (vWF), angiopoietin 1 receptor precursor or tunica intima EC kinase (Tie2/TEK), and CD38 [1719]. Unfortunately, these are surface markers that do not identify and discern exclusively EPCs.

According to the first studies, EPCs were identified as cells positive for both CD34 (HSC’s marker) and VEGFR2 (endothelial marker). Several groups suggested that peripheral blood and BM-derived CD34+ cells are able to behave as ECs; indeed they can express endothelial specific markers and they show endothelial lineage abilities both in vitro and in vivo [2022]. In contrast Case et al. [23] affirmed that CD34+/CD133+/VERGR2+ cells were not EPCs and that these cells, however, could acquire an endothelial phenotype. Furthermore the authors affirmed that CD34+/CD133+/VERGR2+ cells expressed also the CD45 marker, thus representing haematopoietic progenitors and not EPCs. Moreover Madeddu et al. [24] affirmed that the population CD34+/VEGFR2+ is enriched in EPCs, while Friedrich et al. [25] showed that CD133+/CD34/VEGFR2+ cells were able to regenerate vasculature structures and represented immature EPCs which differentiated in mature ECs. Taken together, these contradictory studies suggest that only a part of CD34+ cells can represent EPCs and, probably, EPCs derive from a subpopulation of CD34 positive cells. Since CD34 as well as VEGFR2 can be also expressed by mature ECs, other markers must be used to determinate and isolate EPCs. One of these is CD133. CD133 is also known as AC133 or prominin and it is a highly conserved orphan receptor that could represent another EPCs marker. Although a unique EPCs marker is still undetermined, it is commonly accepted that EPCs, residing in BM or immediately circulating, express CD133/CD34/VEGFR2 and are also known as circulating ECs or CECs, while circulating EPCs maintain CD34 and VEGFR2 but lose CD133 and acquire other endothelial lineage markers [10]. Indeed Peichev et al. [26] asserted that peripheral circulating CD34+/VEGFR2+ cells, that coexpress CD133, are immature EPCs. When they are recruited in the site of damage, these cells become mature under cytokines stimuli and they lose CD133 maintaining CD34 and VEGFR2. But CD133 is also expressed by haematopoietic stem cells like immature EPCs and it is missed on mature ECs [27].

These opposing data suggest that it is difficult to define and isolate exactly EPCs especially in the field of oncology where EPCs are often identified as circulating CD133+ cells. Moreover, the possibility to identify EPCs is strictly correlated with the technics used to evaluate their surface markers.

The number of circulating EPCs is low and variable according to the method and antigens used to identify these cells [28]. To solve this problem, most authors use different culture assays to increase the amount of EPCs from peripheral blood. All protocols for EPCs isolation differ concerning the culture time and most of them are short term protocols (47 days) [29]. Overall, we can count three methods for culturing EPCs ex vivo. In the first method, peripheral blood mononuclear cells (PBMCs) are seeded on dishes precoated with proteins that mimic extracellular matrix (ECM) such as fibronectin, collagen, or gelatin [30]. After short term culture of 47 days, a step essential to remove differentiated ECs and monocytes/macrophages, nonadherent cells are reseeded on dishes. These cells will form in one week colony forming units (CFU) composed of round cells in the centre with spindle shaped attaching cells and present ECs phenotypical characteristics and markers such as CD31, VEGFR2, VEcadherin, and TIE2.

Moreover, Hur et al. [31] demonstrated that the core of these colonies was formed also by CD3+, CD31+, and CXCR4+ cells, i.d. T cells defined as angiogenic T cells. The cells that form CFU take the name of CFU-ECs or early EPCs [3032]. They have lowered proliferation ability, survive in culture condition for not less than 3040 days, and must express not only endothelial markers but also CD14 (myeloid marker) and CD45 (panleukocytic marker) [28]. With the second method, PBMCs are cultured in a medium supplemented with proangiogenic cytokines for 47 days and later nonadherent cells are eliminated.

The adherent cells are able to sustain angiogenesis in vivo and, for this reason, they are defined as circulating angiogenic cells (CACs). They show an endothelial phenotype binding specific endothelial antigens such as lectins as Ulex Europaeus Agglutinin 1 (UEA1) and Bandeiraea Simplicifolia (BS1) lectins, express CD31, Tie2/TEK, VEcadherin, and von Willebrand factor (vWF), and could take up acetylated low density lipoprotein/acLDL. Moreover CACs seem similar to CFUECs because they share marker profile and in vitro properties. For this reason, both cell populations have been often confused or not well discriminated and both CACs and CFUECs are defined as EPCs [2830]. With the last method, we can identify endothelial colony forming cells (ECFCs); since they come from long term culture (until 2 to 3 weeks) of early EPCs, they are also called “late” or “outgrowing” EPCs. The late EPCs acquire mature ECs phenotype expressing markers like CD31, VEGFR2, VEcadherin, and vWF, with CD133 and CD34, and they have a cobblestone-like shape typical of mature ECs. Finally, outgrowth EPCs would differentiate into mature ECs to begin and promote angiogenesis and vasculogenesis [2830]. To elucidate the complexity of several types of EPCs, Prater et al. [33] suggested an interesting hypothesis: CACs were the largest part of cultured EPCs; further they supposed that ECFCs took part in the circulating ECs population and that CD45+ haematopoietic progenitor cells cross with CFUECs in an undetermined manner.

Recent studies demonstrated that ECFCs do not express hematopoietic markers, showing that they do not have a hematopoietic origin. Piaggio et al. [34] proved that ECFCs, unlike CFU-ECs, lack the expression of CD45 and CD14 markers and they also demonstrated that CFU-ECs presented the same mutations of circulating leukocytes from patients with myeloproliferative disease, whereas ECFCs did not. This result highlighted that ECFCs have a different origin from hematopoietic cells. Raemer et al. [35] demonstrated that these ECFCs are able to costimulate T cells as well as monocytes better than mature ECs, such as HUVEC. Finally, Prokopi et al. [36] showed that the expression of mature ECs antigens such as CD31, VEGFR2, and Von Willebrand factor by CFU-ECs is mainly due to a platelet contamination within buffy coat at the moment of cells isolation. Proteomic studies proved that early EPCs uptook endothelial markers from platelets, not because they expressed these endothelial markers themselves. Thus, all these recent studies underlined that only few EPCs are able to form vascular network in vivo and show a higher proliferative ability and these cells are represented by ECFCs [37]. So, ECFCs, which represent only 1% of all the circulating EPCs, are supposed to be true EPCs and they are better described as angiogenic macrophages [38].

3. Key Pathways in Vasculogenesis

There are several pathways which regulate haemangioblasts differentiation and vasculogenesis during embryo development but also EPCs recruitment in postnatal life. These pathways may also be altered in some pathological conditions such as malignancies.

3.1. VEGF and Other Cytokines

Vascular endothelial growth factor plays a key role in regulating both angiogenesis and vasculogenesis.

There are five different isoforms of VEGF generated as a result of alternative splicing from a single VEGF gene (VEGFA, -B, -C, -D, and placenta VEGF also known as PIGF) which interacts with three main tyrosine kinase receptors (VEGFR1, -2, and -3) [39]. The activation of VEGFR induces the mobilization of EPCs towards injured sites, and here the VEGF pathway stimulates their differentiation into mature ECs.

In particular VEGFA and VEGFR1, also known as Flt1, and VEGFR2, also known as Flk1, are expressed during embryo life [40].

VEGFA and its receptors, VEGFR1 and VEGFR2, are presented early in embryonic development. VEGFA is expressed in the extraembryonic endoderm and mesoderm during the formation of blood islands and it is also secreted within the intraembryonic endoderm. VEGFR2 is an early marker of endothelial and hematopoietic precursor cells in blood islands. Shalaby et al. [41] demonstrate that the expression of VEGF and VEGFR is necessary for a correct vasculogenesis process: the lack of VEGFR2 induces the embryo death due to the failure of vasculogenesis and hematopoiesis. Knockdown of VEGF signaling during embryo development implied a decreased cell migration and the consequent defective formation of blood islands. Similarly, deletion of VEGF and VEGFR1 results in embryo lethality due to problems in vascular development. In particular, the lack of a single VEGF allele results in embryo death caused by an improper development of the dorsal aorta and an altered haematopoiesis; the deletion of VEGFR1 induces an inappropriate localization of haemangioblasts in the blood islands; instead the knockdown of VEGFR3 appears to be mainly involved in lymphatic vessels development [42].

Platelet-derived growth factor (PDGF) is strongly associated with VEGF pathway, and it is involved in cell migration during vascular development. In vivo and in vitro studies showed that activating mutations of PDGF receptor (PDGFR) in embryo promote vascular development; instead PDGF antagonists inhibit vasculogenesis and tumor growth in rat model [43].

Another important cytokine involved in vascular development is Transforming Growth Factor β (TGFβ).

Many studies reported its critical role showing how the lack TGFβ results in disorders during yolk sac vasculogenesis and the death of half of the mutant embryos at week 9.510.5; instead the remaining embryos die weeks later due to inflammation [44, 45]. Also the knockdown of TGFβ receptor causes embryonic death at week 10. Stromal cell-derived factor 1 (SDF1) is an important chemokine in EPCs and HSCs mobilization, not only in wound healing and tissue damage but also during organogenesis and embryo vascular development [46].

Endoglin is a transmembrane receptor for TGFβ, which coexists with TGFβ receptors and which is highly expressed in endothelial cells. Mice lacking endoglin die at week 11.5 for defects to vascular system and atypical cardiac development [47]. Liu et al. [48], using mice knocked out for endoglin, demonstrated that endoglin is necessary to ensure the organization of haemangioblasts into tubular structures and that endoglin is required for a correct vasculogenesis process depending on VEGF.

These cytokines have also a crucial role in regulating tumor vasculogenesis contributing to the angiogenic switch in both solid and haematological malignances. The expression of these molecules changes from different stages of tumor growth, remission, and relapse. Many studies reported the altered secretion of proangiogenic molecules such as VEGF, FGF, PDGF, EGF, TGFβ, and angiopoietin within the tumor microenvironment which contribute to EPCs mobilization and differentiation and ECs proliferation. So, in tumor patients a great percentage of ECs undergo mitosis versus the very lower 0,01% of healthy adults, highlighting the idea of an enhanced vessel growth in these pathological conditions [49].

3.2. Notch

Notch signaling is involved in many developmental phases but also in neoplastic processes such as tumor angiogenesis and vasculogenesis, Endothelial to Mesenchymal Transition (EMT), drug resistance, and metastasis. There are four different Notch transmembrane receptors (Notch1, -2, -3, and -4) and five ligands belonging to two different families, Jagged1 and Jagged2, and the ones belonging to the Delta family Delta-like 1 (DLL1), DLL3, and DLL4. The bond of a Notch ligand to the receptor induces three proteolytic cleavages with the formation of the so-called Notch transcriptional domain which translocate into the nuclei and together with other transcriptional factors forms the “Notch transcriptional complex” (NTC). Thus Notch acts as a transcriptional regulator, inducing the expression of many genes related to differentiation and survival, including hairy/enhancer of split (HES), the family of helix-loop-helix transcription factors, cyclin D, and cMyc [50]. Many studies reported that the lacking of Notch receptors or their ligands is involved in vascular defects during embryo development and also in ECs maturation and migration. Fischer et al. demonstrated that the Notch target genes Hey1 and Hey2 are required for a correct embryo vascular development. The knockdown of Hey1 alone induces cardiac defects and a high probability of postnatal death; instead the loss of Hey2 does not result in any particular defects; but the loss of both Hey1 and Hey2 causes embryonic lethality at week 9.5 due to a defective vascular remodeling and the presence of truncated vessels responsible for abundant hemorrhages. This study highlights the importance of these two target genes as principal effectors of vasculogenesis regulated by the Notch pathway [51]. Also the deletion of Notch receptors 1 and 4 and Notch ligand DLL4 results in embryonic death and alteration of vasculature development [52]. Many authors also demonstrated the important role of Notch signaling in the regulation of tumor vasculogenesis and angiogenesis. Alteration of the expression of Notch ligands Jagged1, which enhances tumor angiogenesis, and DLL4, which acts as negative regulator of tumor vasculogenesis, has been discovered in various tumors [53].

3.3. Hedgehog

Hedgehog pathway is involved in embryo development and vasculogenesis and regulates cell proliferation and migration. Hedgehog family includes three different ligands: sonic hedgehog (Shh), Indian hedgehog (Ihh), and desert hedgehog (Dhh). The bind of hedgehog ligands to their transmembrane receptor, Patched, induces a conformational change that removes the repression of the transmembrane Smoothened protein (Smo). The activation of Smoothened regulates the expression of GLI transcriptional activators which activate Hedgehog target genes themselves [54]. All ligands are involved in vasculogenesis. Ihh ligand seems to be necessary for an appropriate blood island formation in early stage of yolk sac vessel development and of lumen formation in murine embryo; mice knocked down for Ihh showed defective vasculogenesis during yolk sac development resulting in embryos death [55]. Dhh ligand instead is activated during embryo gastrulation and is expressed in mature yolk sac mesoderm. Dhh role seems to be similar to those of Ihh and might compensate Ihh inactivation. Shh regulates angiogenesis in different tissue in late phases of embryogenesis. FGF activates hedgehog pathway through Shh and stimulates the expression of VEGF and Ang2. Many studies reported that Shh is involved in regulating EPCs recruitment from bone marrow and in their differentiation into mature endothelial cells [56]. Finally, also an inactivation of Smo protein, which is the main downstream effector of hedgehog pathway, is necessary for a functional vasculogenesis and Vokes et al. [55] demonstrated that mice knocked down for Smo die at week 7.58.0 during embryo life. Maybe hedgehog signaling is able to regulate vasculogenesis through the activation of its target Bone Morphogenetic protein 4 (Bmp4). Inactivation of Bmp4 induces defective vascular development. Recently, a strict relationship between Hh pathway and malignancies has been proved. Chen et al. [57] demonstrated that tumor cells express hedgehog ligands and this signaling pathway is active in the tumor microenvironment. In particular, the activation of canonical hedgehog pathway induces fibroblasts to secrete VEGF and other proangiogenic growth factors, which enhances not only tumor angiogenesis but also the mobilization of EPCs from BM niches.

4. Homing and Mobilization of ECPs

In physiological conditions, the peripheral blood number of circulating EPCs is low because they are located in stem cell niche in the BM where the microenvironment governs EPCs mobilization through high level of stromal cell-derived factor1 (SDF1) and hypoxic conditions. During trauma and wound healing or during cancer progression when the increase of tumor mass causes the angiogenic switch with the production of proangiogenic cytokines and factors (VEGF, basic FGF, PDGF, erythropoietin or EPO, granulocyte colony stimulating factor, or GCSF), BMEPCs, responding to stimuli, are mobilized from BM and they acquire typical characteristics of CECs and arrive at injury site and here they differentiate into mature ECs. The activation of different molecular pathways occurs in EPCs, VEGF pathway being the most important. VEGF is able to activate endothelial nitric oxide synthase (eNOS) that produces nitric oxide [58]. It regulates the activation of matrix metalloproteinases (MMPs), in particular MMP9.

Activated MMP9 promotes the cleavage of membrane bound stem cell cytokine mKitL by stromal cells in the BM niche; thus soluble kit ligand sKitL is released. sKitL stimulates cKit+ EPCs inducing cell mobilization from BM niche into peripheral blood. This migration elicits EPCs activation acting in a transition from a quiescent to a proliferative stage [59]. Moreover VEGF regulates SDF1 and its receptor (CXCR4) that are discovered to be chemotactic for EPCs promoting the recruitment of EPCs into the vascular zone. SDF1 needs other signals to recruit EPCs, such as VEGF. Furthermore SDF1 helps EPCs to remain within the vasculature site [60]. Overall, VEGF interacts with MMP9 and SDF1 developing EPCs release into peripheral bloodstream; consequently in cancer patients, the increase of VEGF levels leads EPCs mobilization from the BMniche to the bloodstream [61, 62]. Moreover, integrins regulate the retention of EPCs in the BMniche, particularly α4 and β3. Indeed studies in vitro and in vivo show that α4 and β3 alterations favor the migration of EPCs from the BM microenvironment to the peripheral blood [4]. In addition, deletion of α4 integrin specifically inhibits EPCs and haematopoietic stem cells mobilization to BM but not to spleen, showing that different integrins expressed on EPCs promote their homing to different tissues [63]. Other studies [64] demonstrate the implication of other integrins in the neovascularization such as β2 integrins and β1 integrins. β2 integrins (also known as CD11/CD18) are found on haematopoietic stem cells and on peripheral-derived EPCs and are involved in cell-cell adhesion and EPCs transmigration through the blood vessels; in fact different studies support that β2 integrins activation promotes the neovascularization ability of EPCs in vivo. But the inhibition of these integrins blocks partially EPCs homing, underlining that there are other integrins involved in EPCs mobilization to damage tissue or tumor mass [64, 65]. β1 integrins are expressed on both ECs and haematopoietic cells. This family governs EPCs mobilization to angiogenic sites and interacts with activated ECs through vascular cell adhesion protein (VCAM) and cellular fibronectin. In particular, α5β1 is overexpressed on circulating EPCs to promote the bind with vessels fibronectin, while α6β1 is also implicated in endothelial tubes formation during neovasculogenesis [66]. Moreover, Qin et al. [67] reported that several integrins are expressed only in circulating and not differentiated EPCs, while others are expressed during EPCs differentiation. For example, during their differentiation, EPCs express α4, α5, and αv integrins that interact with fibronectin underlining the important role of fibronectin in EPCs maturation.

Going into details, once EPCs leave their niche, they are activated and interact with ECs by integrins to ensure their transmigration through endothelial monolayer. But to invade blood vessels, EPCs produce and secrete MMP9 that promotes ECM disruption and its remodelling. Once EPCs arrive at the site of damage or near tumor mass, they can take part in neovascularization in three ways: (1) EPCs are directly incorporated in new vessels, (2) EPCs differentiate in mature ECs, and (3) EPCs produce and secrete proangiogenic factor and cytokines with paracrine effects such as VEGF, bFGF, SDF1, PDGF, insulin-like growth factor (IGF1), macrophage inflammatory protein 1a, and monocyte chemotactic protein 1 (MCP1) [68]. But other molecules stimulate EPCs homing such as granulocyte/macrophage colony stimulating factor (GMCSF) or EPO. Indeed Takahashi et al. [69] demonstrated that animals treated with exogenous GMCSF showed an increase of circulating EPCs; similarly, Bahlmann et al. [70] proved in vitro and in human peripheral blood that recombinant human erythropoietin (rhEPO) is able, in a dose dependent manner, to enlarge functionally active EPCs.

In conclusion, EPCs, which leave the BMniche and are released into the bloodstream, beyond the BM microenvironment control, begin their differentiation, under different stimuli, into CECs to finally become mature ECs activating important pathways involved in injuries repair and tumor progression.

5. EPCs in Haematological Malignancies

CECs are associated with neovasculogenesis in various malignant disorders. Several studies have shown that vasculogenesis in haematologic tumors is closely related to the existence of an adult haemangioblast population that leads to the neoformation of blood vessels in these tumors [71].

As demonstrated by Folkman’s group in 1997 there is an increase in BMMVD in acute lymphoblastic leukemia patients suggesting a correlation between angiogenesis and leukemia progression [72]. MVD increase and high levels of numerous proangiogenic factors have been reported in acute and chronic leukemia and occasionally were correlated with worse survival [73]. The same findings on the role of vasculogenesis were demonstrated later in myeloma, non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS).

5.1. Acute Leukemia

Acute myeloid leukemia (AML) is a heterogeneous haematological disease characterized by the clonal expansion of myeloid blasts in the peripheral blood and BM. AML is the common form of acute leukemia in adults.

The vessels recruitment has a role in the pathogenesis of AML. Indeed Hussong et al. conducted a study on AML patients that showed that MVD is greater in leukemic BM biopsy samples from untreated patients compared to those of normal controls [74]. This study confirmed that a correlation exists between increased BM vascularity and overall survival of leukemia patients and that a higher MVD can contribute to refractory disease [75]. Furthermore, Fiedler et al. [76], investigating the vascular niche, found increased expression of VEGF, as well as VEGFR1 and VEGFR2, in leukemic blasts from patients with AML.

Cultured endothelial human umbilical cord cells (HUVECs) under VEGF stimuli produce a dose dependent increase in GMCSF, suggesting paracrine mechanisms [77]. ECs support adhesion and transmigration subsets of CD34+ normal HSPCs. Several in vitro studies with HUVECs in cocultures with promyelocytic leukemia cells (HL60) exposed to cytarabine showed that these ECs have a protective effect on leukemic myeloblasts. However, recent studies suggest that leukemia cells may have reciprocal effects of enhancing the proliferation of ECs establishing a cyclic positive feedback loop which favors the potential for refractory and relapsed disease [78].

Finally, an increase of circulating angiogenic factors such as VEGF and angiopoietin (Ang2) and the increased angiogenesis in the BM are indicators of high risk of recurrence of disease and early mortality as shown by Madlambayan et al. [79] in mononuclear cells of the BM in AML patients newly diagnosed before treatment. However, the meaning of Ang2 in AML is complex and most likely influenced by VEGF [72, 79].

Acute lymphocytic leukemia (ALL) is the most common form of leukemia in children and is caused by the accumulation of lymphoblasts in the BM. In adult ALL, some studies show the role of angiogenesis and vasculogenesis with increasing evidence that angiogenesis markers play a role in the pathogenesis of patients with ALL.

Hou et al. [80] found a correlation between high levels of cellular VEGF at diagnosis of ALL and the number of leukemic blasts as well as the behavior of the surrounding microenvironment. Conversely at the time of remission the BM angiogenic switch takes place with the secretion of VEGF and other proangiogenic factors in the serum [81]. In fact it can be difficult to distinguish the production and secretion of angiogenic factors reactive compared to a true reflection of the pathophysiological process [82].

Perez-Atayde et al. [72] demonstrated a significant increase of MVD in the BM of 40 children with ALL compared to that in control marrows.

The three-dimensional structure of normal marrows which show single, straight, nonbranching vessels, and leukemic marrows with complex, arborizing branching vessels has been studied. The average number of blood vessels in the BM is significantly higher than in those, normal of the same age [83].

Similarly, serum levels of bFGF but not VEGF were significantly elevated in these children. However, other studies reported increasing levels of both VEGF and bFGF in patients in remission or they failed to detect significant differences in MVD at presentation or remission from children in poor prognostic groups of ALL [84].

5.2. Chronic Leukemia

Chronic lymphocytic leukemia (CLL) is blood and BM disease that usually gets worse slowly. CLL is one of the most common types of leukemia in adults.

In this malignancy, experimental and clinical data suggest that angiogenesis may have a role in the pathogenesis and progression of the disease.

Aguayo et al. [83] showed an increase of the MVD in the BM of patients with CLL, which can reach up to three times compared to healthy controls. A study performed in 2010 of 170 patients with CLL explained that CECs and EPCs are more numerous in CLL than in healthy controls and that this increase correlated with a more aggressive disease. In particular they demonstrated that gene expression profiling of separated waste CECs expressed a molecular model of probable derivation from CLLs; these cells were characterized by an increased proliferation and proangiogenic function but also decreased adhesion to the ECM and the consequent increase in survival compared to normal subjects [85].

Ultimately CECs may be somewhat related to the angiogenic switch which characterizes the transition to a more aggressive stage of the disease; so CECs could represent a new prognostic indicator. Further studies will be used to clarify whether, in CLL patients, CECs can be used to evaluate the effectiveness of treatment and whether patients with elevated CECs may benefit from treatment with the new antiangiogenic drugs [85].

Chronic Myelogenous Leukemia (CML) is a clonal disorder of a pluripotent stem cell. The disease accounts for almost 15% of leukemia cases and may occur at any age.

Lundberg et al. [86] demonstrated that the chronic myeloproliferative diseases, chronic myeloid leukemia, and myelofibrosis were associated with increased MVD in the BM compared to healthy subjects. Data also suggested that VEGF, increased in CML, could be an important signaling molecule to recruit EPCs in these conditions. Also the architecture of the vascular environment in myeloproliferative disorders is much more tortuous and branched than normal. Moreover, the number of vessels and their ramifications increases proportionally with worse prognosis [86].

5.3. Non-Hodgkin’s Lymphomas

These represent a large group of lymphoid tumours, most commonly of B-cell origin, whose clinical presentation and natural history are more variable. The neovessel formation is different depending on the type of lymphoma: it is higher in aggressive subtypes such as in the involved lymph nodes of patients with BCLL (small lymphocytic lymphoma) and Burkitt lymphomas; it is lower in diffuse large B-cell lymphomas and in indolent follicular lymphoma [87]. Preclinical studies have already shown the importance of detecting the level of circulating EPCs during the various stages of malignancies [8].

Igreja and collaborators sought to define the relative importance of circulating EPCs versus EPCs located in the affected tissues. This study performed on CD133+/CD34+/VEGFR2+ EPCs in PB and lymph nodes of patients with NHL highlighted an increased number of circulating EPCs in NHL younger patients with more aggressive disease and reduced levels of EPCs in patients with incomplete response to treatments. Lymph nodes EPCs (LNEPCs) were not only found around the vessels but also could be found scattered throughout the tissue. Genes expressed by LNEPCs encode proangiogenic factors and chemoattractant cytokines that contribute to the expansion of the lymphoma mass. The concomitant presence in NHL patients of both circulating EPCs and LNEPCs indicates that the development of the disease can be monitored by new surrogate markers probably involved in the pathogenesis and vasculogenesis of lymphomas [88].

5.4. Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow failure disorders characterized by an inexorable but variably gradual trend of progressive cytopenias and transformation to AML in approximately 30% of cases [89]. The formation of new vessels is a fundamental process for the development of MDS [90]. Della Porta et al. [91] showed that levels of CECs (CD45 gate as D146+/CD34+ cells) increased in MDS patients compared to CECs controls and that this was particularly true for those without excess blasts. The distinction between EPCs and mature ECs was made by identifying the expression of CD133 in the progenitor to mature ratio. This was higher in patients at diagnosis compared to individuals at followup, suggesting that, in MDS, the mobilization of ECs in the BM is greater in the early stages and then decreases during the disease progression and indicating that the majority of CECs in MDS, but not in healthy individuals, consist of precursor cells. So medullary ECs play a key role in tumor transformation [92]. Furthermore BM microvessel density was found to be related to the CECs and higher in low risk patients. The study by Della Porta et al. [91] adds more guidance to the use of therapies designed to restore a normal interaction between haematopoietic progenitor cells and BM microenvironment.

5.5. Multiple Myeloma

Multiple myeloma (MM) is a debilitating malignancy characterized by the clonal proliferation of neoplastic plasma cells in the BM and a subsequent excess of monoclonal paraprotein in blood and/or urine [9]. In the BM of MM patients HSCs are recruited and induced to differentiate into ECs by the angiogenic cytokines such as VEGF, bFGF, and IGF present in the microenvironment and they participate in the formation of new vessels [93]. Several studies have investigated the role of CECs and EPCs in MM progression. Vacca et al. [94] in 1994 had already shown the increases in parallel with the MVD and the risk of active disease in patients with MM. A study of 75 patients with multiple myeloma showed higher levels of circulating EPCs (defined as D45/CD34+/CD133+/CD31+ cells) in patients with active disease increasing, respectively, from Durie and Salmon phase I to phase III compared to healthy controls.

Circulating EPCs were instead reduced after therapy in patients who achieved at least a partial response [95]. Zhang et al. [96] studying EPCs and CEC by RTPCR and flow cytometry, respectively, confirmed the higher levels of the two cell types in MM patients compared to healthy controls. In particular CECs were six times higher in patients than in controls proportionally to the increase of two markers of disease activity such as serum proteins M and β2 microglobulin. Also a study by the Mayo Clinic showed a strong association between angiogenesis grade and density. In fact, patients with ≤50 microvessels/field survived 5.1 years, while those with more than 50 survived only 2.6 years () and concluded that bone marrow angiogenesis can be a predictor of poor survival in newly diagnosed myeloma [97].

5.6. Conclusions and Therapeutic Perspectives

The use of EPC has been proposed as a therapeutic target in different diseases, for example, the role of EPC in the treatment of cardiovascular diseases. A recent study investigated the possibility of autologous EPCs therapy for therapeutic revascularization and vascular repair in ischemic pathologies [98].

Moreover, during cancer progression, vasculogenesis-mediated EPC would represent an interesting therapeutic target and could act as a potential reference point for the synthesis of new and more effective antiangiogenic drugs [99].

However these therapies require a full knowledge of the mechanisms underlying the recruitment of EPCs [98].

The numerous discoveries of MVD in different tumor diseases have opened a way to EPC therapies, but despite being effective, the antivessel treatment in many patients fails to halt tumor progression.

BM-derived EPC-mediated vasculogenesis is a very important event in promoting the “angiogenic switch.” In haematological malignancies many investigations are still ongoing to characterize more precisely the finest EPCs associated with cancer [10, 99101].

These studies will inform new perspectives for the rational use of antivascular therapies in blood cancers.

Assunta Melaccio is a co-first author.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Antonia Reale and Assunta Melaccio contributed equally to this work.

  1. S. Patan, “Vasculogenesis and angiogenesis,” Cancer Treatment and Research, vol. 117, pp. 3–32, 2004. View at: Publisher Site | Google Scholar
  2. D. S. Charnock-Jones, P. Kaufmann, and T. M. Mayhew, “Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation,” Placenta, vol. 25, no. 2-3, pp. 103–113, 2004. View at: Publisher Site | Google Scholar
  3. T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of putative progenitor endothelial cells for angiogenesis,” Science, vol. 275, no. 5302, pp. 964–967, 1997. View at: Publisher Site | Google Scholar
  4. S. Balaji, A. King, T. M. Crombleholme, and S. G. Keswani, “The role of endothelial progenitor cells in postnatal vasculogenesis: implications for therapeutic neovascularization and wound healing,” Advances in Wound Care, vol. 2, no. 6, pp. 283–295, 2013. View at: Publisher Site | Google Scholar
  5. B. Assmus, J. Honold, V. Schächinger et al., “Transcoronary transplantation of progenitor cells after myocardial infarction,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1222–1232, 2006. View at: Google Scholar
  6. J. Li, Y.-P. Zhang, and R. S. Kirsner, “Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix,” Microscopy Research and Technique, vol. 60, no. 1, pp. 107–114, 2003. View at: Publisher Site | Google Scholar
  7. T. Matsumoto, A. Kawamoto, R. Kuroda et al., “Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing,” American Journal of Pathology, vol. 169, no. 4, pp. 1440–1457, 2006. View at: Publisher Site | Google Scholar
  8. Y. Shaked, F. Bertolini, S. Man et al., “Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis,” Cancer Cell, vol. 7, no. 1, pp. 101–111, 2005. View at: Publisher Site | Google Scholar
  9. R. Ria, A. Reale, A. De Luisi, A. Ferrucci, M. Moschetta, and A. Vacca, “Bone marrow angiogenesis and progression in multiple myeloma,” American Journal of Blood Research, vol. 1, no. 1, p. 7689, 2011. View at: Google Scholar
  10. J. G. Roncalli, J. Tongers, M.-A. Renault, and D. W. Losordo, “Endothelial progenitor cells in regenerative medicine and cancer: a decade of research,” Trends in Biotechnology, vol. 26, no. 5, pp. 276–283, 2008. View at: Publisher Site | Google Scholar
  11. T. Asahara, H. Masuda, T. Takahashi et al., “Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization,” Circulation Research, vol. 85, no. 3, pp. 221–228, 1999. View at: Google Scholar
  12. A. Grochot-Przęczek, M. Kozakowska, J. Dulak, and A. Józkowicz, “Endothelial cell origin, differentiation, heterogeneity and function,” in Angiogenesis and Vascularisation, pp. 3–26, Springer, Vienna, Austria, 2013. View at: Publisher Site | Google Scholar
  13. S.-I. Nishikawa, S. Nishikawa, M. Hirashima, N. Matsuyoshi, and H. Kodama, “Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages,” Development, vol. 125, no. 9, pp. 1747–1757, 1998. View at: Google Scholar
  14. T. L. Huber, V. Kouskoff, H. J. Fehling, J. Palis, and G. Keller, “Haemangioblast commitment is initiated in the primitive streak of the mouse embryo,” Nature, vol. 432, no. 7017, pp. 625–630, 2004. View at: Publisher Site | Google Scholar
  15. K. M. Vogeli, S.-W. Jin, G. R. Martin, and D. Y. R. Stainier, “A common progenitor for haematopoietic and endothelial lineages in the zebrafish gastrula,” Nature, vol. 443, no. 7109, pp. 337–339, 2006. View at: Publisher Site | Google Scholar
  16. C. Furuta, H. Ema, S.-I. Takayanagi et al., “Discordant developmental waves of angioblasts and hemangioblasts in the early gastrulating mouse embryo,” Development, vol. 133, no. 14, pp. 2771–2779, 2006. View at: Publisher Site | Google Scholar
  17. M. Hristov, W. Erl, and P. C. Weber, “Endothelial progenitor cells: mobilization, differentiation, and homing,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1185–1189, 2003. View at: Publisher Site | Google Scholar
  18. N. Quirici, D. Soligo, L. Caneva, F. Servida, P. Bossolasco, and G. L. Deliliers, “Differentiation and expansion of endothelial cells from human bone marrow CD133+ cells,” British Journal of Haematology, vol. 115, no. 1, pp. 186–194, 2001. View at: Publisher Site | Google Scholar
  19. S. Kaushal, G. E. Amiel, K. J. Guleserian et al., “Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo,” Nature Medicine, vol. 7, no. 9, pp. 1035–1040, 2001. View at: Publisher Site | Google Scholar
  20. A. Kawamoto, H. Iwasaki, K. Kusano et al., “CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells,” Circulation, vol. 114, no. 20, pp. 2163–2169, 2006. View at: Publisher Site | Google Scholar
  21. A. A. Kocher, M. D. Schuster, M. J. Szabolcs et al., “Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function,” Nature Medicine, vol. 7, no. 4, pp. 430–436, 2001. View at: Publisher Site | Google Scholar
  22. H. Masuda, C. Alev, H. Akimaru et al., “Methodological development of a clonogenic assay to determine endothelial progenitor cell potential,” Circulation Research, vol. 109, no. 1, pp. 20–37, 2011. View at: Publisher Site | Google Scholar
  23. J. Case, L. E. Mead, W. K. Bessler et al., “Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors,” Experimental Hematology, vol. 35, no. 7, pp. 1109–1118, 2007. View at: Publisher Site | Google Scholar
  24. P. Madeddu, C. Emanueli, E. Pelosi et al., “Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs,” The FASEB Journal, vol. 18, no. 14, pp. 1737–1739, 2004. View at: Publisher Site | Google Scholar
  25. E. B. Friedrich, K. Walenta, J. Scharlau, G. Nickenig, and N. Werner, “CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities,” Circulation Research, vol. 98, no. 3, pp. e20–e25, 2006. View at: Publisher Site | Google Scholar
  26. M. Peichev, A. J. Naiyer, D. Pereira et al., “Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors,” Blood, vol. 95, no. 3, pp. 952–958, 2000. View at: Google Scholar
  27. R. Handgretinger, P. R. Gordon, T. Leimig et al., “Biology and plasticity of CD133+ hematopoietic stem cells,” Annals of the New York Academy of Sciences, vol. 996, pp. 141–151, 2003. View at: Publisher Site | Google Scholar
  28. P. P. Young, D. E. Vaughan, and A. K. Hatzopoulos, “Biologic properties of endothelial progenitor cells and their potential for cell therapy,” Progress in Cardiovascular Diseases, vol. 49, no. 6, Article ID 421429, pp. 421–429, 2007. View at: Google Scholar
  29. G. P. Fadini, D. Losordo, and S. Dimmeler, “Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use,” Circulation Research, vol. 110, no. 4, pp. 624–637, 2012. View at: Publisher Site | Google Scholar
  30. B. Dome, J. Dobos, J. Tovari et al., “Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease,” Cytometry Part A, vol. 73, no. 3, pp. 186–193, 2008. View at: Publisher Site | Google Scholar
  31. J. Hur, H.-M. Yang, C.-H. Yoon et al., “Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies,” Circulation, vol. 116, no. 15, pp. 1671–1682, 2007. View at: Publisher Site | Google Scholar
  32. P. S. Lee and K. K. Poh, “Endothelial progenitor cells in cardiovascular diseases,” World Journal of Stem Cells, vol. 6, no. 3, pp. 355–366, 2014. View at: Google Scholar
  33. D. N. Prater, J. Case, D. A. Ingram, and M. C. Yoder, “Working hypothesis to redefine endothelial progenitor cells,” Leukemia, vol. 21, no. 6, pp. 1141–1149, 2007. View at: Publisher Site | Google Scholar
  34. G. Piaggio, V. Rosti, M. Corselli et al., “Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker,” Blood, vol. 114, no. 14, pp. 3127–3130, 2009. View at: Publisher Site | Google Scholar
  35. P. C. Raemer, S. Haemmerling, T. Giese et al., “Endothelial progenitor cells possess monocyte-like antigen-presenting and T-cell-co-stimulatory capacity,” Transplantation, vol. 87, no. 3, pp. 340–349, 2009. View at: Google Scholar
  36. M. Prokopi, G. Pula, U. Mayr et al., “Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures,” Blood, vol. 114, no. 3, pp. 723–732, 2009. View at: Publisher Site | Google Scholar
  37. J. D. Pearson, “Endothelial progenitor cells—hype or hope?” Journal of Thrombosis and Haemostasis, vol. 7, no. 2, pp. 255–262, 2009. View at: Publisher Site | Google Scholar
  38. J. D. Pearson, “Endothelial progenitor cells-an evolving story,” Microvascular Research, vol. 79, no. 3, pp. 162–168, 2010. View at: Publisher Site | Google Scholar
  39. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, “Vascular endothelial growth factor (VEGF) and its receptors,” The FASEB Journal, vol. 13, no. 1, pp. 9–22, 1999. View at: Google Scholar
  40. K. L. Marcelo, L. C. Goldie, and K. K. Hirschi, “Regulation of endothelial cell differentiation and specification,” Circulation Research, vol. 112, no. 9, pp. 1272–1287, 2003. View at: Google Scholar
  41. F. Shalaby, J. Rossant, T. P. Yamaguchi et al., “Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice,” Nature, vol. 376, no. 6535, pp. 62–66, 1995. View at: Publisher Site | Google Scholar
  42. S. Patel-Hett and P. A. D'Amore, “Signal transduction in vasculogenesis and developmental angiogenesis,” International Journal of Developmental Biology, vol. 55, no. 4-5, pp. 353–369, 2011. View at: Publisher Site | Google Scholar
  43. V. W. Wong and J. D. Crawford, “Vasculogenic cytokines in wound healing,” BioMed Research International, vol. 2013, Article ID 190486, 11 pages, 2013. View at: Publisher Site | Google Scholar
  44. M. C. Dickson, J. S. Martin, F. M. Cousins, A. B. Kulkarni, S. Karlsson, and R. J. Akhurst, “Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice,” Development, vol. 121, no. 6, pp. 1845–1854, 1995. View at: Google Scholar
  45. J. J. Letterio, A. G. Geiser, A. B. Kulkarni, N. S. Roche, M. B. Sporn, and A. B. Roberts, “Maternal rescue of transforming growth factor-β1 null mice,” Science, vol. 264, no. 5167, pp. 1936–1938, 1994. View at: Publisher Site | Google Scholar
  46. K. E. McGrath, A. D. Koniski, K. M. Maltby, J. K. McGann, and J. Palis, “Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4,” Developmental Biology, vol. 213, no. 2, pp. 442–456, 1999. View at: Publisher Site | Google Scholar
  47. D. Y. Li, L. K. Sorensen, B. S. Brooke et al., “Defective angiogenesis in mice lacking endoglin,” Science, vol. 284, no. 5419, pp. 1534–1537, 1999. View at: Publisher Site | Google Scholar
  48. Z. Liu, F. Lebrin, J. A. Maring et al., “Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factorinduced angiogenesis,” PLoS ONE, vol. 9, no. 1, Article ID e86273, 2014. View at: Publisher Site | Google Scholar
  49. K. Podar and K. C. Anderson, “The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications,” Blood, vol. 105, no. 4, pp. 1383–1395, 2005. View at: Publisher Site | Google Scholar
  50. L. A. Milner and A. Bigas, “Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation,” Blood, vol. 93, no. 8, pp. 2431–2448, 1999. View at: Google Scholar
  51. A. Fischer, N. Schumacher, M. Maier, M. Sendtner, and M. Gessler, “The notch target genes Hey1 and Hey2 are required for embryonic vascular development,” Genes and Development, vol. 18, no. 8, pp. 901–911, 2004. View at: Publisher Site | Google Scholar
  52. S.-M. Kwon, C. Alev, and T. Asahara, “The role of notch signaling in endothelial progenitor cell biology,” Trends in Cardiovascular Medicine, vol. 19, no. 5, pp. 170–173, 2009. View at: Publisher Site | Google Scholar
  53. Z. Liu, F. Fan, A. Wang, S. Zheng, and Y. Lu, “Dll4-Notch signaling in regulation of tumor angiogenesis,” Journal of Cancer Research and Clinical Oncology, vol. 140, no. 4, pp. 525–536, 2014. View at: Publisher Site | Google Scholar
  54. J. Jiang and C.-C. Hui, “Hedgehog signaling in development and cancer,” Developmental Cell, vol. 15, no. 6, pp. 801–812, 2008. View at: Publisher Site | Google Scholar
  55. S. A. Vokes, T. A. Yatskievych, R. L. Heimark et al., “Hedgehog signaling is essential for endothelial tube formation during vasculogenesis,” Development, vol. 131, no. 17, pp. 4371–4380, 2004. View at: Publisher Site | Google Scholar
  56. T. Nagase, M. Nagase, M. Machida, and T. Fujita, “Hedgehog signalling in vascular development,” Angiogenesis, vol. 11, no. 1, pp. 71–77, 2008. View at: Publisher Site | Google Scholar
  57. W. Chen, T. Tang, J. Eastham-Anderson et al., “Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 23, pp. 9589–9594, 2011. View at: Publisher Site | Google Scholar
  58. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, “Activation of nitric oxide synthase in endothelial cells by Akt—dependent phosphorylation,” Nature, vol. 399, no. 6736, pp. 601–605, 1999. View at: Publisher Site | Google Scholar
  59. B. Heissig, K. Hattori, S. Dias et al., “Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand,” Cell, vol. 109, no. 5, pp. 625–637, 2002. View at: Publisher Site | Google Scholar
  60. G. C. Schatteman, M. Dunnwald, and C. Jiao, “Biology of bone marrow-derived endothelial cell precursors,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 292, no. 1, pp. H1–H18, 2007. View at: Publisher Site | Google Scholar
  61. G. Fürstenberger, R. Von Moos, R. Lucas et al., “Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer,” British Journal of Cancer, vol. 94, no. 4, pp. 524–531, 2006. View at: Publisher Site | Google Scholar
  62. J. W. Y. Ho, R. W. C. Pang, C. Lau et al., “Significance of circulating endothelial progenitor cells in hepatocellular carcinoma,” Hepatology, vol. 44, no. 4, pp. 836–843, 2006. View at: Publisher Site | Google Scholar
  63. L. M. Scott, G. V. Priestley, and T. Papayannopoulou, “Deletion of α4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing,” Molecular and Cellular Biology, vol. 23, no. 24, pp. 9349–9360, 2003. View at: Publisher Site | Google Scholar
  64. C. Urbich and S. Dimmeler, “Endothelial progenitor cells: characterization and role in vascular biology,” Circulation Research, vol. 95, no. 4, pp. 343–353, 2004. View at: Publisher Site | Google Scholar
  65. E. Chavakis, A. Aicher, C. Heeschen et al., “Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells,” The Journal of Experimental Medicine, vol. 201, no. 1, pp. 63–72, 2005. View at: Google Scholar
  66. C. Bouvard, B. Gafsou, B. Dizier et al., “α6-integrin subunit plays a major role in the proangiogenic properties of endothelial progenitor cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1569–1575, 2010. View at: Publisher Site | Google Scholar
  67. G. Qin, M. Ii, M. Silver et al., “Functional disruption of α4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization,” Journal of Experimental Medicine, vol. 203, no. 1, pp. 153–163, 2006. View at: Publisher Site | Google Scholar
  68. F. Caiado, C. Real, T. Carvalho, and S. Dias, “Notch pathway modulation on bone marrow-derived vascular precursor cells regulates their angiogenic and wound healing potential,” PLoS ONE, vol. 3, no. 11, Article ID e3752, 2008. View at: Publisher Site | Google Scholar
  69. T. Takahashi, C. Kalka, H. Masuda et al., “Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization,” Nature Medicine, vol. 5, no. 4, pp. 434–438, 1999. View at: Publisher Site | Google Scholar
  70. F. H. Bahlmann, K. de Groot, J.-M. Spandau et al., “Erythropoietin regulates endothelial progenitor cells,” Blood, vol. 103, no. 3, pp. 921–926, 2004. View at: Publisher Site | Google Scholar
  71. M. Moschetta, Y. Mishima, I. Sahin et al., “Role of endothelial progenitor cells in cancer progression,” Biochimica et Biophysica Acta, vol. 1846, no. 1, pp. 26–39, 2014. View at: Publisher Site | Google Scholar
  72. A. R. Perez-Atayde, S. E. Sallan, U. Tedrow, S. Connors, E. Allred, and J. Folkman, “Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia,” American Journal of Pathology, vol. 150, no. 3, pp. 815–821, 1997. View at: Google Scholar
  73. S. Faderl, K.-A. Do, M. M. Johnson et al., “Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia,” Blood, vol. 106, no. 13, pp. 4303–4307, 2005. View at: Publisher Site | Google Scholar
  74. J. W. Hussong, G. M. Rodgers, and P. J. Shami, “Evidence of increased angiogenesis in patients with acute myeloid leukemia,” Blood, vol. 95, no. 1, pp. 309–313, 2000. View at: Google Scholar
  75. I. Kuzu, M. Beksac, M. Arat, H. Celebi, A. H. Elhan, and S. Erekul, “Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival,” Leukemia and Lymphoma, vol. 45, no. 6, pp. 1185–1190, 2004. View at: Publisher Site | Google Scholar
  76. W. Fiedler, U. Graeven, S. Ergün et al., “Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia,” Blood, vol. 89, no. 6, pp. 1870–1875, 1997. View at: Google Scholar
  77. A. F. List, “Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies,” The Oncologist, vol. 6, supplement 5, pp. 24–31, 2001. View at: Google Scholar
  78. A. Trujillo, C. McGee, and C. R. Cogle, “Angiogenesis in acute myeloid leukemia and opportunities for novel therapies,” Journal of Oncology, vol. 2012, Article ID 128608, 9 pages, 2012. View at: Publisher Site | Google Scholar
  79. G. J. Madlambayan, A. M. Meacham, K. Hosaka et al., “Leukemia regression by vascular disruption and antiangiogenic therapy,” Blood, vol. 116, no. 9, pp. 1539–1547, 2010. View at: Publisher Site | Google Scholar
  80. H.-A. Hou, W.-C. Chou, L.-I. Lin et al., “Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia,” Leukemia Research, vol. 32, no. 6, pp. 904–912, 2008. View at: Publisher Site | Google Scholar
  81. S. Yetgin, I. Yenicesu, M. Çetin, and M. Tuncer, “Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia,” Leukemia and Lymphoma, vol. 42, no. 1-2, pp. 83–88, 2001. View at: Publisher Site | Google Scholar
  82. A. Bikfalvi and Z. C. Man, “Angiogenic factors are hematopoietic growth factors and vice versa,” Leukemia, vol. 8, no. 3, pp. 523–529, 1994. View at: Google Scholar
  83. A. Aguayo, H. Kantarjian, T. Manshouri et al., “Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes,” Blood, vol. 96, no. 6, pp. 2240–2245, 2000. View at: Google Scholar
  84. M. A. Pulè, C. Gullmann, D. Dennis, C. McMahon, M. Jeffers, and O. P. Smith, “Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance,” British Journal of Haematology, vol. 118, no. 4, pp. 991–998, 2002. View at: Publisher Site | Google Scholar
  85. G. M. Rigolin, R. Maffei, L. Rizzotto et al., “Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance,” Cancer, vol. 116, no. 8, pp. 1926–1937, 2010. View at: Publisher Site | Google Scholar
  86. L. G. Lundberg, R. Lerner, P. Sundelin, R. Rogers, J. Folkman, and J. Palmblad, “Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity,” The American Journal of Pathology, vol. 157, no. 1, pp. 15–19, 2000. View at: Google Scholar
  87. D. Ribatti, B. Nico, G. Ranieri, G. Specchia, and A. Vacca, “The role of angiogenesis in human non-Hodgkin lymphomas,” Neoplasia, vol. 15, no. 3, pp. 231–238, 2013. View at: Publisher Site | Google Scholar
  88. C. Igreja, M. Courinha, A. S. Cachaço et al., “Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients,” Haematologica, vol. 92, no. 4, pp. 469–477, 2007. View at: Publisher Site | Google Scholar
  89. V. Klimek, “Myelodysplastic syndromes (MDS),” Best Practice & Research Clinical Haematology, vol. 28, no. 1, p. 12, 2015. View at: Google Scholar
  90. P. Korkolopoulou, E. Apostolidou, P. M. Pavlopoulos et al., “Prognostic evaluation of the microvascular network in myelodysplastic syndromes,” Leukemia, vol. 15, no. 9, pp. 1369–1376, 2001. View at: Publisher Site | Google Scholar
  91. M. G. Della Porta, L. Malcovati, G. M. Rigolin et al., “Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes,” Leukemia, vol. 22, no. 3, pp. 530–537, 2008. View at: Publisher Site | Google Scholar
  92. B. A. Peters, L. A. Diaz Jr., K. Polyak et al., “Contribution of bone marrow-derived endothelial cells to human tumor vasculature,” Nature Medicine, vol. 11, no. 3, pp. 261–262, 2005. View at: Publisher Site | Google Scholar
  93. A. Vacca, R. Ria, D. Ribatti et al., “A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma,” Haematologica, vol. 88, no. 2, pp. 176–185, 2003. View at: Google Scholar
  94. A. Vacca, D. Ribatti, L. Roncali et al., “Bone marrow angiogenesis and progression in multiple myeloma,” British Journal of Haematology, vol. 87, no. 3, pp. 503–508, 1994. View at: Publisher Site | Google Scholar
  95. A. Bhaskar, R. Gupta, L. Kumar et al., “Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma,” Leukemia & Lymphoma, vol. 53, no. 4, pp. 635–640, 2012. View at: Publisher Site | Google Scholar
  96. H. Zhang, V. Vakil, M. Braunstein et al., “Circulating endothelial progenitor cells in multiple myeloma: implications and significance,” Blood, vol. 105, no. 8, pp. 3286–3294, 2005. View at: Publisher Site | Google Scholar
  97. RA. Mesa, C. A. Hanson, S. V. Rajkumar, G. Schroeder, and A. Tefferi, “Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia,” Blood, vol. 96, no. 10, pp. 3374–3380, 2000. View at: Google Scholar
  98. D. Sukmawati and R. Tanaka, “Introduction to next generation of endothelial progenitor cell therapy: a promise in vascular medicine,” American Journal of Translational Research, vol. 7, no. 3, pp. 411–421, 2015. View at: Google Scholar
  99. M. Ammendola, C. Leporini, M. Luposella et al., “Targeting endothelial progenitor cells in cancer as a novel biomarker and anti-angiogenic therapy,” Current Stem Cell Research & Therapy, vol. 10, no. 2, pp. 181–187, 2015. View at: Google Scholar
  100. D. J. Nolan, A. Ciarrocchi, A. S. Mellick et al., “Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization,” Genes & Development, vol. 21, no. 12, pp. 1546–1558, 2007. View at: Google Scholar
  101. D. Gao, D. J. Nolan, A. S. Mellick, K. Bambino, K. McDonnell, and V. Mittal, “Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis,” Science, vol. 319, no. 5860, pp. 195–198, 2008. View at: Publisher Site | Google Scholar

Copyright © 2016 Antonia Reale et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.


text:
Four years of Modi govt: How India’s economic narrative is up for grabs in 2019 elections

Public perception on bread and butter economic issues will matter more than achievements such as India being the fastest growing major economy.
Prime Minister Narendra Modi during an address in Bandipora, Srinagar.(PTI FIle Photo)
Prime Minister Narendra Modi during an address in Bandipora, Srinagar.(PTI FIle Photo)
Updated on May 26, 2018 07:30 AM IST
Copy Link
Hindustan Times, New Delhi | ByRoshan Kishore

The National Democratic Alliance (NDA) government will complete four years on May 26, 2018.

Headline numbers suggest that the economy has done well in these four years. India is the fastest growing major economy in the world. This growth has not come at the cost of high inflation or fiscal deficit. At no point of time has the Consumer Price Index, the benchmark measure of inflation for Reserve Bank of India’s inflation targeting agreement with the government, exceeded its targeted range.

Stock markets and foreign exchange reserves are significantly higher than what they were in May 2014. To be sure, external factors such as cheap oil prices and lower interest rates in developed countries have aided some of these achievements.

But then governments’ fortunes are always contingent on cyclical factors. Unless there is a big deficiency in this year’s monsoon, there is no reason to believe that the government will not be able to wriggle itself out of the problem posed by the rise in international oil prices at least till the elections.

Asking government-owned oil companies to take a cut in profits or even allowing a slippage in fiscal deficit are some of the options which can be exercised. A severe drought will of course unsettle these plans by demanding a big chunk of the resources at hand. It is also likely that election year will see a generous increase in Minimum Support Prices to please the distress ridden farming community.

Does this mean that the government will not face any headwinds on the economic front as it heads into the 2019 election cycle? Not necessarily. Headline economic numbers do not matter in the day-to-day lives of common people. Their judgment is more likely to be swayed by bread and butter issues.

Job creation was the biggest promise of the present government on the economic front. Due to non-availability of the next round of National Sample Survey Office (NSSO) statistics, it is impossible to conclusively settle the debate on job creation under the present government.

Both the opposition and the government are making varied claims about employment generation. While an academic debate must wait for the NSSO numbers to be released, it is public perception which will matter more as far as elections are concerned.

Statistics from RBI’s Consumer Confidence Survey do not paint a rosy picture. The survey asks respondents about their perceived current employment level compared to a year ago and expected employment levels in the next year. Latest numbers show a marked deterioration on both counts compared to when the government took over (See Chart 1).

Tracking the movement in these numbers can help us understand how the economic narrative has evolved under the present government.

Net expectation of employment a year ahead reached its peak in the June 2014 quarter, which is when Narendra Modi became Prime Minister. This suggests that people genuinely believed Achhe Din, the key slogan of Modi’s 2014 campaign, had arrived. This number held steady till December 2014 and then kept declining till the September 2015 quarter. The fact that India experienced two back-to-back drought years in 2014 and 2015 explains this trend.

The curve remained flat till September 2016 and showed a minor spike in the November 2016 quarter, which included a festive season followed by a normal monsoon after a two-year gap. Things changed drastically afterwards. The index kept falling for one full year until November 2017.

Demonetisation’s cash squeeze and teething troubles in implementation of Goods and Services Tax (GST) are bound to have played a role in this. The trend in last two quarters is indeterminate.

The movement in perceived present employment in comparison to the past year has followed a similar trend except, it peaked in December 2014 instead of the June 2014 quarter.

What does this mean for the political fortunes of the present government? It is difficult to say. Both these indices had started recovering from September 2013 onwards, a year before the 2014 general elections. Despite this the incumbent government suffered a big loss.

There is one trend, however, which probably explains the 2014 result. Expectation about future employment was rising at a much faster rate than perceived employment in comparison to last year in the run-up to the 2014 elections.

As has been pointed out earlier, the former peaked in June 2104 with the formation of the Modi government. This shows that the trend might have been a manifestation of political consolidation behind the BJP (then in opposition) before the elections. In case a similar trend is seen in the next few quarters, it could be bad news for the present government too. This also describes the central challenge for the opposition as far as setting the economic narrative is concerned. It is not enough to say that the government has failed to deliver.

Voters would like to know what the next version of Achhe Din would be like.

Close Story
Story Saved
Saved Articles
My Reads
Sign out
New Delhi 0C
Wednesday, December 01, 2021


text:
609 Main at Texas

“Through intelligent design that is sensitive to the environment, we have created a magical place that allows tenants to serve their customers at a higher level while recruiting more successfully for their organizations, retaining the people they have and letting them achieve their best. It's what sets this building apart,” said Jon Pickard, a New Haven-based architect, once a protégé of Cesar Pelli, and now the Co-owner of Pickard Chilton, one of the most respected names in modern corporate architecture.

609 Main at Texas is a true next-generation office tower developed by Hines in the heart of Downtown Houston. The project is part of the Hines CalPERS Green Fund (HCG), a partnership exclusively focused on the development of office buildings certifiable through the U.S. Green Building Council. 609 Main at Texas follows and bookends the firm's transformative 811 Main development, formerly known as BG Group Place, another HCG project two blocks away. 811 Main was the winner of the ULI 2014 Development of Distinction Award.

At a commanding 48 stories, 609 Main at Texas is carefully crafted to foster the best possible tenant experience while offering cutting-edge green concepts and artfully reflecting the sky. Its north and south facades extend upward, culminating in a dramatic diagonal crown to create a highly visible landmark that contributes to the vitality of the CBD. The narrower east and west facades are slightly recessed, and the subtly faceted exterior is clad in 10-foot, floor-to-ceiling glass with brushed stainless steel accents.

Vertical blades are incorporated in the east and west facades, enhancing the tower's silhouette and offering solar shading. Computer-controlled LED illumination within the east and west recesses, and the tower's sloped peak, accentuate the structure's presence on the nighttime skyline. From inside the building, the multi-directional views are made more dramatic by the unusually tall and wide vision windows, which also provide more access to available daylight.

609 Main at Texas is futuristic. Tenants love going to work there!

Gerald D. Hines, Founder, Hines

Amenities in the 1,073,000-square-foot tower include a hotel-style lobby with an 11-story atrium, a reflecting pool, a café, and spaces for networking. Tenants enjoy access to their own private 7,000-square-foot, high-performance fitness center, an 8,000-square-foot conference center and private rooftop sky gardens in select tenant spaces. Efficient building components include a sophisticated under-floor HVAC system allowing for more individual comfort and cleaner air, speedy “smart” elevators, and highly advanced safety systems.

Parking for 1,700 cars is provided in an internal 13-level garage (11 above-grade and two below-grade floors). Located at the nexus of Metro and bus lines, the property also offers a direct connection to the downtown pedestrian tunnel system.

Completed in 2017, 609 Main at Texas provides the finest office space in Houston for tenants interested in a high-profile business address with a green package aimed at productivity and health – and a cool factor— at a competitive rate. Gerald Hines, who built most of the notable skyscrapers in downtown Houston, was once quoted as saying that people expect each Hines building to be better than the last. He agrees with Jon Pickard and says, “609 Main at Texas is futuristic. Tenants love going to work there!”

View the Property


text:
Council Highlights

Council Highlights -  July 09, 2019

Citizens' Minute with Council

Residents are welcome to speak to Council about issues, events, celebrations or concerns during Minute with Council. At the beginning of each regular Council Meeting, Mayor Michaels opens the floor to the public to speak and share with Council members, administration and meeting observers.

Jessica Lineham
Lineham came on behalf of Options West Yellowhead, presenting a number of events that the organization will be hosting over the summer months.

Presentations are required to be arranged through the Executive Assistant, so that presenters can be sure time is set aside for their presentations on the Council agenda. Find out more about how to be a delegation by following this link.

1. Living and Working In Recovery Program - Presented by Duane Martin

 Find the presentation in the agenda package, available here

2. Hinton Mountain Bike Association Wheeled Park Project - Presented by Jay Hore and Everett Tetz

Find the presentation in the agenda package, available here

Public Hearings

In some instances, Council is required to conduct public hearings regarding land use bylaws, rezoning, etc., or on any other matter council deems appropriate.

The were no public hearings.

Action Items

1. Beaver Boardwalk Committee Bylaw and Terms of Reference - Presented by Hans van Klaveren
The Beaver Boardwalk - Concept Design and Feasibility Report has been presented and discussed at Standing Committee providing Council information regarding the current state and future rehabilitation options for the Beaver boardwalk.

To date there has been a lot of additional information and feedback brought forward, for example:
  • Alberta Environment and Parks (AEP), consultants and the public at-large. Council has expressed that a thorough process is required to assist in their decision on the Beaver Boardwalk and its future.
  • At the Standing Committee Meeting of May 14, 2019, Council directed Administration to bring back terms of reference for a Beaver Boardwalk committee no later than the June 18, 2019 Standing Committee.
  • At the Standing Committee Meeting of June 18, 2019, consensus was achieved to:
    • Amend the Beaver Boardwalk Committee Terms of Reference for a high-level vision to be presented to and adopted by Council prior to the proposed Beaver Boardwalk Committee’s third meeting.
    • Amend the Terms of Reference to include the Mayor and two appointed Town of Hinton Council representatives to the Beaver Boardwalk Committee.
It was moved that Council provide first and second reading to Bylaw #1138, the Beaver Boardwalk Committee Bylaw. These motions carried. Council then gave unanimous consent for third reading, and gave the third reading.

It was then moved that Council appoint Mayor Michaels, Councillor Ostashek and Councillor Nelson to the Beaver Boardwalk Committee, with Councillor Race as an alternate. This motion carried.

2. Appointment of Committee Members - Presented by Mayor Michaels
View Mayor Michaels recommended changes in the agenda package, available here. It was moved that Councillor Albert Ostashek be removed from the Hinton Police / Town Liaison Committee. This motion carried. It was then that Councillor Trevor Haas be appointed to the Hinton Police / Town Liaison Committee. This motion also carried.

3. Property Tax Assessments – Additional Property Tax Revenue - Presented by Carla Fox
In 2018 a larger than normal reassessment occurred for the Town, which Administration did not anticipate during the preparation of the 2019 budget. Taxation revenue was estimated by taking the approved taxation increase of 4.4% and applying this to the previous years’ mill rate (0.0053553 residential mill rate * 4.4% increase). This calculation only accounted for approximately $50,000 of the inflationary increase in assessment values and this has resulted in an unexpected taxation revenue increase of approximately $510,870. Unless otherwise directed by Council, Administration will bring back, to a committee meeting, a report on suggested options for dealing with the unbudgeted property taxation surplus. It was moved that Council direct Administration to bring a report to a future Standing Committee meeting regarding assessment policy options including split notices and supplemental assessments. This motion carried. It was then moved that Council direct Administration to schedule a discussion on options for the 2019 property tax surplus by the end of September 2019. This motion also carried.

4. Energy Agreement - Presented by Martin Taylor
This report is before Council to obtain decisions from Council on with whom to procure electrical and natural gas for all municipal facilities and to decide how much of a “certified green” component, if any, to have for our electricity purchase. The Town has participated in the Alberta Municipal Services Corporation (AMSC) aggregate program since 2004. Our current agreement expired December 31, 2018. As such, Administration must enter into a new Agreement to procure electricity and natural gas for all Town-owned facilities. It was moved that Council defer the decision on the energy agreement until August 2019 pending a report supporting information regarding implications of certified green power.

In Camera

In-camera is a legal term meaning in private; When a Council goes in-camera, it means the Council meeting is closed to the public. In general terms, the exceptions include matters where disclosures could be harmful to personal privacy, individual or public safety, law enforcement, intergovernmental relations, or economic or other interests; reveal confidential evaluations, local public body confidence, or advice from officials; or disclose information that is subject to legal privilege.

There were in motions coming out of in camera.

Administrative Inquiries

If Councillors have queries they would like to submit to admin, this will be the time at which they do. This is in accordance with Council's procedural bylaw.

There were no inquiries.

Notice of Motion

If Councillors have motions they wish to lodge, this will be the time at which they do. This is in accordance with Council's procedural bylaw.

There were no motions.

Information Items

Councillor Jo-Ann Race: Councillor Race reported having attended a seminar in Edson where the importance of lobbying provincial governments was explored.

Councillor Dewly Nelson: Councillor Nelson reported his involvement in the Town of Hinton Staff Canada Day BBQ, and in the Canada Day Parade. Nelson also shared his hearing a great deal of positive feedback surrounding the Canada Day fireworks display.

Councillor Albert Ostashek: Councillor Ostashek spoke to his involvement in the Town of Hinton's Canada Day Parade float, as well as thanking administration for assisting in preparing floats for the Councillors to take part.

Councillor Trevor Haas: Councillor Haas spoke to his own attendance at the lobbying meeting, as well as reporting attendance at a Golf Society meeting, where the impact of the rainy season and efforts to increase memberships, including no initiation fee signups, were discussed.

Councillor Tyler Waugh: Councillor Waugh reported his attendance at the Canada Day Parade, thanking Councillors for taking part and the Chamber for holding the event. Waugh went on to iterate the importance of volunteering at community events, reminding that the Fohn is a volunteer run tradition.

Mayor Marcel Michaels: Mayor Michaels reported having also taken part in the Staff BBQ, as well as his own attendance at the Golf Society meeting, detailing that while the weather has impacted the organization, the society is doing better than the previous year. Michaels concluded by speaking to a meeting during the day with the Chamber regarding the next Beer and Blue Jeans event.

CAO Martin Taylor: CAO Taylor shared information regarding July 20ths Coffee with a Cop event at the Carmichael location of Tim Hortons, and shared gratitude for Peter Vanas involvement and assistance over his time with the organization.

Town of Hinton Newsflash

Don't Play with your Trash image

Don't Play With Your Trash

Put the bins wheels to the road - or have to put your wheels to the road as you drive your refuse to the landfill.

The Town of Hinton ISB staff have noticed a significant amount of improperly placed bins on residential streets, and have begun an education campaign with Communications to help everyone understand how to place your bins.

Council Video Recordings

As some residents may have noticed, we have recently experienced difficulties with our streaming video provider online. The service provider has changed the accepted methods of posting, which has made all older videos in the inventory non-functioning. These non-functioning videos will removed from the inventory for the time being, however, administration is investigating ways of making a larger library available for residents to access online. In the interim, a new format has been selected, and new recordings are being posted as before; however, the new format is slightly larger, and so less videos will be accessible online than in years past. Recordings of the videos are also available on DVDs at the Hinton Municipal Library, which can be checked out and viewed on either computers or DVD players, or by contacting the Town of Hinton should those DVD recordings not be available.

The Town of Hinton is on Facebook!

As over 1700 people have already figured out - The Town of Hinton now has a corporate Facebook page! This new service adds another resource to the communications toolbelt, and will house information on many different areas; some days, you’ll see information on bylaws, others recreation programs, others information about council decisions or highlights from Council meetings. We will, however, endeavour to ensure that we are sharing content relevant to the widest possible audience. Like us today by clicking here!

You can view the entire agenda package here.

The next Regular Council meeting will be held August 20, 2019, at 4pm
in the Council Chambers.

Powered by
CivicSend - A product of CivicPlus


text:
Christmas Party Funfair Hire

If you are looking to plan a Christmas Party to remember, full of festive fun, long lasting memories and some staff bonding to boot let us help you by organising your Ultimate Festive Funfair. We can provide white knuckle rides, traditional funfair rides, sideshows including a 4-storey fun-house as well as game stalls, food stalls and giant inflatable slides! We’ll work with you to help you create seasonal, festive fun for you and your staff whether you are holding your party indoors or outdoors, no matter the size of the venue. We’ve worked with many corporate companies, universities, schools, councils and small business owners, so we have the experience you need to make the festive season 2018 one to remember. Give us a call on 0330 056 4333 or email our team,

Contact Us


text:
If this is your first visit, please be sure to check out the FAQ by clicking the link above.
You will have to register before you can post: click the register link above to proceed.
To start viewing posts, select the forum that you want to visit from the selection below.

What Books Did You Get For Christmas....

Retired Threads
Lucy Pick
Posts: 48
Joined: March 2010

Post by Lucy Pick » Sun January 2nd, 2011, 2:57 pm

I only got one book this Xmas --- very unusual for me --- Michael Chabon's The Amazing Adventures of Cavalier and Klay. I think it just fits the scope of this board.

User avatar
Posts: 72
Joined: August 2009
Location: Texas, USA

Post by CrimsonPetal » Tue January 4th, 2011, 5:30 am

Ooh! I got some good ones:

Mariana by Susanna Kearsley
Charlotte and Emily by Jude Morgan
Revolution by Jennifer Donnelly
Cheri and The Last of Cheri by Colette
Love, Janis by Laura Joplin

User avatar
Avid Reader
Posts: 344
Joined: July 2009
Location: NT, Australia

Post by Veronica » Fri March 25th, 2011, 12:53 am

[quote=""LoveHistory""]Jakes is one of my favorites, and I loved that one. Strongest of the trilogy in my opinion.[/quote]

I have to say that I struggle to finish this book after watching the tv-series... I try and read a page here and there to finish it but yeah, once you start at the wrong end (tv-show) you're done. :p
"Time you enjoy wasting, was not wasted"

Return to “Archives”


text:
Buy Tickets

Agriculture and Technology Highlight Summer Theme Months at Jamestown Settlement & Yorktown Victory Center

Agriculture and Technology Highlight Summer Theme Months
at Jamestown Settlement & Yorktown Victory Center

Summer programs in  August explore aspects of 17th- and 18th-century Virginia agriculture and technology through a variety of family friendly interpretive programs and hands-on demonstrations.

Tools of the Trade – August 1-31, 2011

 Navigational tools with SC interpreter.jpg

At Jamestown Settlement, visitors will discover the tools used by Powhatan Indians before English contact to hunt game, cultivate crops, prepare food, build homes and make clothing. Aboard re-creations of the ships that brought English colonists to Virginia in 1607, visitors can examine techniques for sail handling and navigation to learn how mariners determined ships’ speed, direction and distance traveled. At the riverfront discovery area, learn the value of tools in trade among European, Powhatan and African cultures, as well as compare and contrast tools used for catching fish and constructing watercraft. Within the re-created colonial fort, visitors will explore the trades of English settlers and the tools they used, from woodworking to repairing tools at the blacksmith’s forge, to the matchlock muskets and armor worn by soldiers.

Breaking flax at the Yorktown Victory Center farmAt the Yorktown Victory Center, visitors to the re-created 1780s farm can see demonstrations of tools farmers used for planting and tending gardens, processing flax into cloth, harvesting tobacco and cooking over an open hearth. At the Continental Army encampment, visitors will discover the technology that enabled soldiers to use flintlock muskets during the American Revolution and see daily demonstrations of weaponry. Special programs each day will allow visitors to learn about the tools used by an artillery crew, followed by a firing of an artillery piece.  Daily demonstrations also highlight the techniques and implements used by physicians and surgeons to care for sick and wounded soldiers.

Watch a video about Matchlock and Flintlock muskets.

Jamestown Settlement and Yorktown Victory Center are open 9 a.m. to 5 p.m. daily (until 6 p.m. June 15 through August 15). Visitors can save 20% on a combination ticket to both museums: $20.00 for adults and $10.00 for ages 6-12. Children under 6 receive complimentary admission.


text:
Tyler Cruise excitedly waits for his new stepmom, Kit Mercer, to arrive. Once she arrives, it’s obvious that he lusts for her, though he tries to play it cool. Tyler takes Kit’s suitcase for her, wanting to impress her, but it’s too heavy for him. Kit finds this endearing, and tells him not to worry about it, as she picks up the suitcase herself. As the days go by, Tyler tries to find other ways to impress Kit. He attempts to hammer a nail into the wall to hang her new painting, but ends up accidentally hammering his thumb, right in front of Kit. Ouch! Next, he tries to move furniture for her, but isn’t strong enough. After failing so many times, Tyler becomes visibly embarrassed and upset. While Tyler mopes, Kit tries to comfort him. She tries to get Tyler to open up to her, and he says that he won’t ever be able to impress a girl if he can’t do stuff like hammer nails and move furniture. Kit continues to soothe him, saying that he should just be himself, but she’s also here to give him advice on getting a girlfriend if he needs extra help. When she finds out that Tyler doesn’t have much experience with touching girls, Kit surprises him by letting him touch and squeeze her breasts. Then for a further lesson, she invites him to touch and lick her pussy… looks like Tyler’s going to get the action he wanted after all!

AdultTime, MommysBoy

Published: October 16, 2021

Duration: 0:38:24
Views: 4.24K

Add a Public Comment

Your email address will not be published. Required fields are marked *


text:
Academic Coaches

Patsy Sewell M.S.

Academic Coach

Serving: Master of Education and Credential Students

Sorry, but a Javascript-enabled browser is required to view the email link.

| x3542

College of Mount Saint Vincent (Bronx, NYC)- B.S. in Psychology with a minor in Philosophy.

California State University, Dominguez Hills- M.S. in College Counseling.

Advice to prospective Students?

Take the leap of faith and continue your education! I know pursuing a graduate degree can seem intimidating, but I can assure you that here at Hope International University, you will have an abundance of support. Our professors and academic coaches are dedicated to assisting our students in achieving their goals. We look forward to celebrating your successes with you!

How do you spend your free time?

I am a former collegiate student-athlete, so I love using my free time to mentor and coach the next generation of volleyball players. I currently coach for a local club volleyball team. When I am not coaching, I spend my free time with my family and friends by hiking or finding local small restaurants and coffee shops to support.